Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, 1449614535, Iran.
Department of Hematology Oncology, Iran University of Medical Sciences, Tehran, Iran.
BMC Complement Med Ther. 2023 Sep 26;23(1):339. doi: 10.1186/s12906-023-04165-8.
The prevalence of breast cancer and its mortality rate are increasing rapidly among women worldwide. On other hand, the courses of chemotherapy as the main treatment for these patients are too much exhaustive and annoying. This study was designed to evaluate the use of synbiotics (probiotics + prebiotics) supplementation as a safe and inexpensive adjuvant treatment in reducing common chemotherapy side effects in women with breast cancer.
The current study was conducted on 67 women with definitive diagnosis of breast cancer who were hospitalized to receive one-day chemotherapy sessions, and met the inclusion criteria. The patients were randomly allocated to the intervention or control group to receive synbiotics or placebo, respectively. They received oral consumption of synbiotics supplements twice a day for 8 weeks. The primary outcome was the changes in severity or experience of chemotherapy complication, analyzed by intention to treat (ITT). The instruments included 7 validated questionnaires which were used to assess chemotherapy complications in the initiation, 4 weeks and 8 weeks after intervention. Dietary intake was measured by 24-h dietary recall at the beginning, week 4 and week 8. Data were analyzed by SPSS software version 24. P-value < 0.05 was considered as statistically significant.
67 breast cancer patients participated in the study. 8 weeks after intervention and adjusting the confounders, the severity of chemotherapy complications including unnormal defecation (P = 0.005) and fatigue (P < 0/001) decreased significantly in the synbiotics group compared to the placebo group. Furthermore, nausea/vomiting (P = 0.015), and anorexia (P < 0.001) were decreased at the end of the study compared to the first visit, but it was not statistically significant compared to the placebo group.
Synbiotics supplementation during chemotherapy can potentially reduce the severity of fatigue and abnormal defecation. It can help reduce anorexia and nausea/vomiting.
This study was registered in the Iranian Registry of Clinical Trials (IRCT) (registered code: IRCT20091114002709N56) (date of registration: 5/5/2021). Direct link to the trial page: https://www.irct.ir/trial/54559 .
乳腺癌的患病率及其死亡率在全球范围内呈快速上升趋势。另一方面,化疗作为这些患者的主要治疗方法,过程过于繁重和令人厌烦。本研究旨在评估使用合生元(益生菌+益生元)补充剂作为一种安全且廉价的辅助治疗方法,以减少女性乳腺癌患者常见的化疗副作用。
本研究纳入了 67 名经确诊患有乳腺癌且需住院接受为期一天的化疗的女性患者,这些患者符合纳入标准。将这些患者随机分配至干预组或对照组,分别接受合生元或安慰剂治疗。他们每天口服合生元补充剂两次,持续 8 周。主要结局为采用意向治疗(ITT)分析评估化疗并发症严重程度或体验的变化。采用 7 个经过验证的问卷评估化疗开始时、干预后 4 周和 8 周的化疗并发症,这些问卷在干预前后都有使用。通过 24 小时膳食回顾法在研究开始时、第 4 周和第 8 周测量膳食摄入量。采用 SPSS 软件版本 24 进行数据分析。P 值<0.05 被认为具有统计学意义。
67 名乳腺癌患者参与了本研究。干预 8 周后,调整混杂因素后,与安慰剂组相比,合生元组的化疗并发症严重程度(包括异常排便(P=0.005)和疲劳(P<0.001))显著降低。此外,与首次就诊时相比,在研究结束时恶心/呕吐(P=0.015)和厌食(P<0.001)也有所减少,但与安慰剂组相比无统计学意义。
化疗期间补充合生元可能有助于减轻疲劳和异常排便的严重程度,并减少厌食和恶心/呕吐。
本研究在伊朗临床试验注册中心(IRCT)注册(注册号:IRCT20091114002709N56)(注册日期:2021 年 5 月 5 日)。直接链接到试验页面:https://www.irct.ir/trial/54559 。